Please login to the form below

Not currently logged in


This page shows the latest respiratory news and features for those working in and with pharma, biotech and healthcare.

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

of diseases, including dermatological diseases such as prurigo nodularis and atopic dermatitis, respiratory diseases such as asthma and CRSwNP, and gastrointestinal diseases such as eosinophilic esophagitis.”.

Latest news

More from news
Approximately 28 fully matching, plus 615 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 86 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 50 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 31 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....